Advertisement

PharmacoEconomics

, Volume 10, Issue 1, pp 79–92 | Cite as

Decision Analysis of Helicobacter pylori Eradication Therapy Using Omeprazole with Either Clarithromycin or Amoxicillin

  • Ann-Marie Craig
  • Peter G. Davey
  • Mo Malek
  • Frank Murray
Original Research Article

Summary

In patients with duodenal ulcer, omeprazole plus clarithromycin (OC) has achieved Helicobacter pylori eradication rates of about 80%, compared with 50% for omeprazole plus amoxicillin (OA). The drug acquisition costs for OC are 102.92 pounds sterling (£) compared with £38.96 for OA using generic amoxicillin and £51.63 using the proprietary brand ‘Amoxil’ (costs for 2-week regimens in 1995). The aim of this analysis was to estimate the total healthcare costs to the general practitioner (GP) of eradication therapy using a simple generalised model.

Data about current practice in the UK were obtained from 502 respondents in a survey of hospital specialists and GPs. It was assumed that patients would derive no benefit from eradication therapy unless they had a duodenal ulcer, and that all OA patients received generic amoxicillin. The survey confirmed that OA was the commonest eradication therapy prescribed by UK GPs at that time. Three distinct patient groups were identified: patients with proven duodenal ulcer who were already receiving maintenance treatment with a histamine H2 receptor antagonist, and new patients with dyspepsia who were subdivided into those aged above or below 45 years.

Patients receiving maintenance treatment for a duodenal ulcer would be prescribed eradication therapy by their GP without further endoscopy. If dyspepsia recurred after eradication therapy, they would be referred to a gastroenterologist, who would perform an endoscopy to confirm the recurrence of ulceration. In this model, the expected total healthcare costs (i.e. the costs of drug acquisition and subsequent treatment when required) following prescription of eradication therapy were lower for OC (£157) than for OA (£173).

New patients aged over 45 years would be referred for endoscopy because of the risk that dyspepsia might be the initial presentation of gastric cancer. If duodenal ulceration was found, eradication therapy would be prescribed and, if dyspepsia remained or recurred, the patient would be referred back to the gastroenterologist. In this case, it was considered unlikely that a further endoscopy would be performed. Thus, the healthcare costs associated with failure of eradication in these patients were less than for patients on maintenance treatment, and the expected total healthcare costs were higher for OC (£349) than for OA (£335).

Finally, a new patient aged under 45 years with dyspepsia would have eradication therapy prescribed on the basis of a clinical diagnosis of duodenal ulcer plus serological evidence of infection with H. pylori. Continuation or recurrence of dyspepsia would result in referral to a gastroenterologist, who would perform an endoscopy. The total expected healthcare costs were higher for OC (£253) than for OA (£251).

The cost effectiveness of OA was sensitive to changes in the default costs (i.e. the average costs from the survey used in the decision analysis), particularly in patients <45 years old. In these patients, OC would become the cheaper option if amoxicillin were prescribed by brand name instead of in generic form. In this patient group, the outcome was crucially dependent on the accuracy of the clinical diagnosis of duodenal ulcer; if this was at least 60%, then OC would be the cheaper regimen.

Overall, the model clearly shows that the higher drug cost of OC is likely to be substantially offset by savings in other healthcare costs. If the direct healthcare costs of OC are higher than OA, then the decision maker must consider the indirect and intangible costs associated with failure of eradication therapy.

Keywords

Omeprazole Duodenal Ulcer Pylorus Infection Dyspepsia Triple Therapy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    MRC funds study into non-ulcer dyspepsia and HP eradication. Pharm Bus News 1994 Dec: 12–3Google Scholar
  2. 2.
    Axon ATR. Helicobacter pylori infection. J Antimicrob Chemother 1993; 32 Suppl. 4: 61–8PubMedCrossRefGoogle Scholar
  3. 3.
    Hawkey CJ. Eradication of Helicobacter pylori should be pivotal in managing peptic ulceration: eradication largely prevents relapse. BMJ 1994 Dec; 309: 1570–2PubMedCrossRefGoogle Scholar
  4. 4.
    Szymusiak-Mutnick B, Mutnik AH. Application of decision analysis in antibiotic formulary choices. J Pharm Technol 1994; 10: 23–6PubMedGoogle Scholar
  5. 5.
    Thornton JG, Lilford RJ, Johnson N. Decision analysis in medicine. BMJ 1992; 304: 1099–103PubMedCrossRefGoogle Scholar
  6. 6.
    ABPI Data Sheet Compendium 1994–95. London: Datapharm Publications Ltd, 1994Google Scholar
  7. 7.
    Bell GD, Powell KU, Burridge SM, et al. Omeprazole plus antibiotic combinations for the eradication of metronidazole-resistant Helicobacter pylori. Aliment Pharmacol Ther 1992; 6: 751–8PubMedCrossRefGoogle Scholar
  8. 8.
    Saunders JHB, Oliver RJ, Higson DL. Dyspepsia: incidence of non-ulcer disease in a controlled trial of ranitidine in general practice. BMJ 1986; 292: 665–8PubMedCrossRefGoogle Scholar
  9. 9.
    Katelaris PH, Patchett SE, Zhang ZW, et al. A randomized prospective comparison of clarithromycin versus amoxycillin in combination with omeprazole for eradication of Helicobacter pylori. Aliment Pharmacol Ther 1995; 9: 205–8PubMedCrossRefGoogle Scholar
  10. 10.
    Gardner MJ, Altman DG. Calculating confidence intervals for proportions and their differences. In: Gardner MJ, Altman DG, editors. Statistics with confidence. London: BMJ, 1989: 28–33Google Scholar
  11. 11.
    Logan RPH, Schaufelberger HD, Gummett PA, et al. Eradication of Helicobacter pylori with dual therapy [abstract]. The Second International Conference on the macrolides, azalides and streptogramins; 1994 Jan; VeniceGoogle Scholar
  12. 12.
    Finkler SA. The distinction between cost and charges. Ann Intern Med 1982; 96: 102–9PubMedGoogle Scholar
  13. 13.
    Vacani PF, Malek MMH, Davey PG. Cost of gentamicin assays carried out by microbiology laboratories. J Clin Path 1993; 46: 890–5PubMedCrossRefGoogle Scholar
  14. 14.
    Hughes D. Costing consultations in general practice: towards a standardized method. Fam Pract 1991; 8: 388–93PubMedCrossRefGoogle Scholar
  15. 15.
    Croft-Jeffreys C, Wilkinson G. Estimated costs of neurotic disorder in UK general practice 1985. Psychol Med 1989; 19: 549–58PubMedCrossRefGoogle Scholar
  16. 16.
    Twaddle SEJ, Porter AMD, Howie JGR, et al. Why costs of consultations in general practice vary. BMJ 1990; 301: 644–5PubMedCrossRefGoogle Scholar
  17. 17.
    Shiell A, Wright K. Counting the cost of community care. York: Centre for Health Economics, University of York, 1988Google Scholar
  18. 18.
    Wright K, Cairns JA, Snell M. Costing care. Sheffield: Joint Unit for Social Sciences Research, University of Sheffield, 1981Google Scholar
  19. 19.
    Fry J. Facts on general practice. Oxford: Radcliffe Medical Press, 1992Google Scholar
  20. 20.
    Davey P, Rutherford D, Graham B, et al. Repeat consultations after antibiotic prescribing for respiratory infection in one general practice. Br J Gen Pract 1994; 44: 509–13PubMedGoogle Scholar
  21. 21.
    Shulkin DJ, Kinosian B, Glick H, et al. The economic impact of infections: an analysis of hospital costs and charges in surgical patients with cancer. Arch Surg 1993; 128: 449–52PubMedCrossRefGoogle Scholar
  22. 22.
    Wheeldon NM, MacDonald TM, Flucker CJ, et al. Echocardiography in chronic heart failure in the community. Q J Med 1993; 86: 17–23PubMedGoogle Scholar

Copyright information

© Adis International Limited 1996

Authors and Affiliations

  • Ann-Marie Craig
    • 1
  • Peter G. Davey
    • 1
  • Mo Malek
    • 1
  • Frank Murray
    • 2
  1. 1.The Pharmacoeconomics Research Centre, Department of Clinical Pharmacology, Ninewells Hospital and Medical SchoolUniversities of Dundee and St AndrewsDundee/St AndrewsScotland
  2. 2.Department of Clinical PharmacologyNinewells Hospital and Medical SchoolDundeeScotland

Personalised recommendations